Skip to content

Safety overdose study intake foods containing plant extracts

Safety overdose study intake foods containing plant extracts. : Open-label study - Safety overdose study intake foods containing plant extracts. : Open-label study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000055690
Enrollment
25
Registered
2024-10-02
Start date
2024-10-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Subjects of men and women aged 20 to 64 (2) Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing.

Exclusion criteria

Exclusion criteria: (1) Subjects with a history of diabetes, liver disease, renal disease, gastrointestinal disease, heart disease, respiratory disease, peripheral angiopathy, or other serious disease (2) Subjects who have undergone gastrointestinal surgery (3) Subjects with abnormal liver and renal function test values (4) Subjects who are currently undergoing treatment for a disease (5) Subjects who are allergic to food or drugs (6) Subjects who have consumed olives, olive oil, or products containing these in the past and experienced allergic reactions or poor physical condition (7) Subjects with anemia symptoms (8) Women who wish to become pregnant (including possible pregnancy) or lactating women during participation in this study (9) Subjects who play intense sports and subjects who are on a diet (10) Subjects with extremely irregular eating habits (11) Subjects who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period (12) Subjects who are continuously treated with pharmaceuticals (including OTC and prescription drugs) (13) Subjects who drink more than 40 g of average daily pure alcohol (14) Subjects who smoke an average of 21 or more cigarettes a day (15) Subjects who are participating or will participate in other clinical trials at the start of this study (16) Subjects who are judged to be unsuitable for the study by the investigator.

Design outcomes

Primary

MeasureTime frame
Adverse event Physical examination (blood pressure, pulse) Laboratory test values (Hematology, blood biochemistry, urinalysis)

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness Support Co., Ltd. Clinical Trial Division

mterashima@oneness-sup.co.jp06-4801-8917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026